

1 **A Systematic Review of the Association between the Age of Onset of Spinal-**
2 **Bulbar Muscular Atrophy (Kennedy's Disease) and the Length of CAG Repeats in**
3 **the Androgen Receptor Gene**

4

5 Dante J. Bellai¹ & Mark G. Rae^{1#}

6

7 ¹Department of Physiology, Western Gateway Building, University College Cork, Cork,
8 Ireland

9

10

11 #Corresponding author

12 E-mail: m.rae@ucc.ie (M.R.)

13 Short title: **Systematic Review of age of weakness onset in SBMA and CAG repeat**
14 **length in the androgen receptor gene**

15

16

Abstract

1
2
3 **Background:** Spinal bulbar muscular atrophy (SBMA) is an X-linked recessive motor
4 neuron disorder which is caused by the presence of ≥ 38 CAG repeats in the androgen
5 receptor gene. Relatively little is known about SBMA, but existing literature indicates a
6 relationship between CAG repeat number and the onset age of some motor symptoms
7 of SBMA. This literature review explored the effect of larger CAG repeats on the age of
8 weakness onset compared to shorter length CAG repeats in male SBMA patients.

9 **Methods:** Three databases were searched (MEDLINE, SCOPUS, and Web of Science;
10 Oct 2021) along with targeted searches in Cambridge University Press and Annals of
11 Neurology. 514 articles were initially identified, of which 13 were included for qualitative
12 synthesis.

13 **Results:** Eleven of the thirteen articles identified a statistically significant inverse
14 correlation between CAG repeat length and age of weakness onset in SBMA. Five
15 studies indicated that SBMA patients with fewer CAG repeats (*e.g.* 35-37) had an older
16 age of weakness onset than patients with a greater number (*e.g.* >40) of CAG repeats.
17 The minimum number of CAG repeats associated with weakness was numbered in the
18 mid-to-late thirties.

19 **Conclusion:** Identification of a relationship between CAG repeat number and weakness
20 may enable earlier detection and intervention for SBMA.

21 Limitations of this review include the restriction to English-only studies and differences
22 in statistical methodology used in each study. We recommend that future studies use
23 interviews, chart reviews, and standardized scoring methods to reduce effects of
24 retrospective bias on reporting SBMA signs and symptoms.

1 **Key words:**

2 Spinal-bulbar muscular atrophy. CAG repeat. Inverse correlation.

3 **Declarations:**

4 Ethics approval: not applicable

5 Consent for publication: not applicable

6 Availability of data and materials: The search data analysed during the current study are
7 available from the corresponding author (M.R.) upon reasonable request.

8 Competing interests: none

9 Funding: not applicable

10 Author's Contributions: D.B. – Search, sorting and analysis of data. Author and editor of
11 article. M.R. – Corresponding author, check of search and data analysis, and editor, of
12 article.

13 Acknowledgements: none

14

15

16

17

Background

1
2 Spinal-bulbar muscular atrophy (SBMA), or Kennedy's disease, is an X-linked
3 recessive motor neuron disorder associated with greater than 38 CAG repeats in the
4 androgen receptor gene (1), that affects approximately 1/40,000 men (although
5 prevalence is greater in certain locations, such as the Vaasa region of Finland) (2).
6 Increased CAG expansion induces toxic polyQ-AR fragments, resulting in the disruption
7 of transcription, mitochondrial function, protein cycling, cell signaling pathways and
8 autophagy (1,3). The average age of onset of SBMA is in the third or fourth decade and,
9 although female carriers display some symptoms of the condition such as distal motor
10 deficits, cramping and/or fasciculations (1), men are much more severely impacted (4)
11 with symptoms that include dysarthria, dysphagia, gynecomastia, cramping,
12 fasciculations and tremor (1).

13 Generally, SBMA follows a gradual progression with postural tremors of the
14 upper limbs starting in the early thirties (5). In addition to the onset of dysarthria and
15 dysphagia in the forties, lower limb motor deficits also develop, eventually requiring the
16 use of walking aids in the fifth decade (5). Finally, patients become wheelchair-bound
17 by, or during, their sixth decade (5). Patients with bulbar musculature implicated early-
18 stage SBMA often die from recurrent aspiration pneumonia in their fifties (6).

19 Although it is known that the age of onset of non-motor manifestations of SBMA
20 is independent of CAG repeat length, primary literature does indicate that there is also a
21 clear negative correlation between the age of onset of motor manifestations and CAG
22 repeat number (for review see (4)). Although several studies (5–17) have pondered the
23 relationship between CAG repeat number and the age of the most frequent symptom of

1 SBMA, weakness (18), to date, no systematic review has specifically focused on the
2 possible connection between these two factors. As such, herein we seek to address this
3 deficit by exploring the effect of a greater number of CAG repeats on the age of
4 weakness onset in comparison to a lower number of CAG repeats in male SBMA
5 patients (between the ages of 11 and 83) who did not suffer from other major chronic
6 illnesses.

7 Given that very little is known about the aetiology of SBMA, probably due to its
8 relatively low prevalence in the population, and that current treatments for SBMA only
9 facilitate symptom management, men with the condition should be identified as soon as
10 possible in order for treatment to begin promptly (4). As such, any addition to the
11 SBMA-associated literature which increases understanding of the disease must be
12 welcomed.

13

14

Objectives

15 Primary literature was reviewed in order to:

- 16 1. Explore whether or not the association between CAG repeat number and
17 age of onset of symptoms of SBMA was, or was not, significant.
- 18 2. Determine what minimum and maximum number of CAG repeats was
19 associated with weakness onset in SBMA.

20

Materials and Methods

Study eligibility

Inclusion criteria (see Table 1) were carefully prepared such that they enabled identification of as many articles as possible that addressed the relationship between CAG repeat number and the specific age of onset of weakness in SBMA patients. Studies that were selected must have included at least some male SBMA patients, with female only studies being excluded. Only studies that examined SBMA patients (with or without female carriers) that had no other major health conditions such as a concomitant diagnosis of schizophrenia, were included. Studies that involved patients with health conditions that commonly co-occur with SBMA such as type II diabetes were included. In addition, the selected age profile of participants had to range from 11 to 83, which was the most common age range of study participants that was encountered in our literature search.

Any form of peer-reviewed, primary research study (*e.g.* case control study, longitudinal study, randomized controlled trial, observational quantitative, mixed methods, *etc.*), as long as it was written in English and not conducted using animals, was eligible for inclusion. However, reviews, commentaries and/or editorials were excluded. Both freely available texts as well as those that could only be purchased (7) were included as long as they could be accessed online. Given the rare nature of the disease and the relative dearth of available literature pertaining to it, we did not apply a date range to our searches and as such studies were accepted even if they were several decades old.

1 **Table 1. Inclusion and exclusion criteria.**

	Inclusion	Exclusion
Intervention	Studies that specifically compared CAG repeat expansion with the onset of muscle weakness in SBMA patients	Studies that addressed activities of daily living but did not specifically compare the onset of weakness with CAG repeat expansion
Population	Male SBMA patients only, or mixed male SBMA patients and female carrier patient populations aged 11-83 with SBMA	Studies that were specific to female carriers
Participants	Male SBMA patients (with or without female carriers) that had no other major health conditions or that had health conditions that commonly co-occur with SBMA such as Type II Diabetes	SBMA patients (with or without female carriers) that had other major health problems such as Schizophrenia
Outcomes	Studies that quantified the number of CAG repeats and compared it with the age at which weakness of any kind (upper limb, lower limb <i>etc.</i>) was first reported	Studies that identified the relationship between CAG repeats and age at onset as being defined as the age at which any symptoms appear (not specifically weakness)
Date	Given that it is a rare disease, any study may be included no matter how old	N/A
Language	Studies written in English	Studies that were not written in English
Types of publication	Any kind of primary literature including: RCTs, longitudinal, case-control, mixed methods studies, observational quantitative, <i>etc.</i>	Review articles / commentaries / editorial articles
Availability	Both freely available full texts and those that had to be purchased	Articles that were not available online
Peer reviewed	Studies published in a peer-reviewed journal	Studies not published in a peer-reviewed journal

2

3

1 **Study Identification**

2
3 Searches were conducted between September and October 2021, by an
4 independent reviewer, and after searching ‘Spinal Bulbar Muscular Atrophy’ and ‘CAG
5 repeat’ on EBSCO, the most commonly cited database was PubMed (*a.k.a.* MEDLINE).
6 PubMed was searched using the following combined terms that were designed to
7 address three concepts: “spinal bulbar muscular atrophy”, “age of onset of muscle
8 weakness”, and “CAG repeat”, which yielded 116 results. Additional searches were
9 made of the SCOPUS and Web of Science databases, utilizing variations of the same
10 three concepts, which generated 390, and three results, respectively. Individual
11 searches were also conducted in two journals: firstly, Cambridge University Press
12 where the abbreviated term “SBMA” was used (yielding two results), and the Annals of
13 Neurology: Wiley Online Library where the search terms for a specific author of interest
14 (“Manabu Doyu”) were used, in addition to the disease of interest (“spinal bulbar
15 muscular atrophy”). This search yielded six results (see Appendix A, S1 for list of search
16 terms and also Fig. 1 for the process utilized for our searches).

17

18 **Study Selection**

19 As SBMA is a relatively rare disease that has not been extensively researched to date,
20 we wished to find as many eligible articles as possible. As such, search filters were not
21 applied during the initial website searches. Results from the PubMed, SCOPUS, and
22 Web of Science database searches, in addition to the Annals of Neurology and
23 Cambridge University Press searches, yielded a total of 515 results (Fig 1, see
24 fig1.docx) that were uploaded to EndNote.

**Fig 1. Flow chart of screening, and criteria for inclusion and exclusion of articles
(8)**

Duplicates were identified and removed using both the duplicate remover function on EndNote, and manually as titles were sorted. This resulted in 346 titles from databases being excluded, with 5 articles identified from individual journal searches also being excluded (Fig. 1). Titles that mentioned SBMA and clinical signs or symptoms and / or pathophysiology, as well as those that mentioned a relationship between CAG repeats and the onset of muscle weakness in male SBMA patients (with or without a female carrier population being part of the study) were included. Ultimately, 91 articles passed the initial title screening process (Fig. 1 and Table 2). Articles were then further screened based on their abstract and full text, which resulted in the exclusion of a further 78 articles. This left a final tally of 13 papers that addressed the aims of this study and which met all of our aforementioned inclusion criteria (Fig. 1).

Table 2. Excluded studies from databases based on abstract/full text.

Full text not in English	16
Did not explicitly compare age of onset of weakness with CAG repeat length in SBMA patients	32
Review/commentary/editorial paper	24
Not available online	2
Not a human study	4
Total excluded	78

Results

Our literature search yielded 13 papers eligible for inclusion in this review. The study design of these 13 articles was as follows: ten quantitative observational (7,9–17), one quantitative longitudinal prospective (18), and two quantitative longitudinal retrospective studies (5,19). There were four Japanese studies (5,7,9,12), one German (11), one Canadian (18), one Polish (13), one Taiwanese (19), one Italian (10), two Korean (14,17), one Chinese (16), and one American study (15). Table 4 summarizes the main results of each study. Populations varied depending on the country in which each study took place. Sample sizes ranged between 14 to 223 patients.

1 **Table 3. Summary of studies that are included in this review article.**

2

Author (Year), Title	Objective	Study Type, Population, Sample Size, Country	Study Methodology	Key Findings	Strengths and Limitations	Future Directions
Fu <i>et al.</i> , (2013), Long-term Follow-up of Spinal and Bulbar Muscular Atrophy in Taiwan	To investigate the long-term prognosis of SBMA and early diagnosis of SBMA.	1. Quantitative longitudinal retrospective. 2. Male Taiwanese SBMA patients from Chang Gung Memorial Hospital in Linkou, Taiwan with a mean age of 43. 3. 21 patients from 14 families. 4. Taiwan	Patients were selected from 1993 to 2010 and were studied through patient interviews and chart reviews to determine the onset age of symptoms and signs of SBMA like weakness. Genomic DNA was extracted to measure the CAG repeats. Serum creatine kinase in addition to other proteins were also measured. Nerve conduction studies were performed on SBMA patients and 20 healthy controls -- specifically the median, ulnar and sural nerves.	1. Insignificant inverse correlation between the length of CAG repeats and the onset of weakness. Most commonly reported symptoms included hand tremor, pectoral fasciculation and limb weakness. 2. Nerve conduction studies only initially showed decreased compound motor action potentials and sensory nerve action potentials between controls and SBMA patients. 3. Functional disability was slowly progressive -- only three patients became wheelchair bound. 4. Creatine kinase was elevated in 17/18 patients. 5. CAG repeat range 42-53 (mean 47 ± 3).	Authors indicated that study was limited by its retrospective nature and limited sample size.	The authors recommended that, in future, larger sample sizes could be used in prospective studies to clarify the functional progression, in addition to the clinical and electrophysiological decline of SBMA patients.
Doyu <i>et al.</i> , (1992), Severity of X-linked Bulbosplinal Neuropathy Correlates with size of the Tandem CAG Repeat in AR Receptor Gene	To examine the relationship between CAG repeats and age of onset of SBMA.	1. Quantitative observational. 2. Members of 21 Japanese families with confirmed SBMA. Age range of 31 - 83 at examination. 3. 26 patients 4. Japan	Patients were selected from 21 available pedigrees and were screened for first symptoms including limb weakness. Scored using an activity of daily living scoring system. Genomic DNA was extracted and PCR was performed to measure the number of CAG repeats, which were then correlated with weakness and other symptoms.	1. Number of CAG repeats was significantly correlated with age of onset of limb weakness ($r = -0.596$, $p < 0.001$) and age-adjusted scored disability ($r = 0.446$, $p < 0.03$). 2. CAG repeat range, 40-55.	Authors did not provide any strengths or weaknesses.	No further comment from the authors.
Sperfeld <i>et al.</i> , (2002), X-linked Bulbosplinal Neuronopathy	To define age of onset of SBMA in addition to determining early symptoms of SBMA	1. Quantitative observational. 2. Male patients from a neuromuscular outpatient clinic. Average age at	Medical history was taken and medical records were reviewed. 30 patients had genomic DNA extracted and amplified using PCR to identify the number of CAG repeats. Then correlated with symptoms of onset. Creatine kinase and blood glucose also measured. Nerve conduction	1. Correlation between CAG repeats and the age of onset of weakness ($r = -0.65$; $p < 0.01$), but not age of onset of SBMA. Weakness is not an initial symptom. 2. Early symptoms include gynecomastia, premature exhaustions and muscle pain. 3. No correlations were found between occurrence of non-motor signs in addition to creatine kinase levels, tremor and additional	Authors did not provide any strengths or weaknesses.	No further comment from the authors.

		<p>examination was 48.9 years.</p> <p>3. 34 patients with genetically proven SBMA.</p> <p>4. America</p>	<p>studies were performed on the sural and radial nerve. Electromyography performed in one proximal and one distal muscle in at least 1 extremity. Magnetic and somatosensory evoked action potentials were measured. Muscle biopsies were taken from 11 patients.</p>	<p>myopathic changes in muscle prosections.</p> <p>4. Adolescent onset is possible.</p> <p>5. CAG repeat range of 40-42.</p>		
<p>Rosenbohm <i>et al.</i>, (2018), The Metabolic and Endocrine Characteristics in Spinal and Bulbar Muscular Atrophy</p>	<p>Systematic phenotyping German SMBA cohort by assessing endocrine, metabolic and neuromuscular status.</p>	<p>1. Quantitative observational..</p> <p>2. Male German patients with confirmed SBMA from neuromuscular referral centers in Universities of Berlin, Bochum, Dresden, Halle, Hannover, Rostock, Ulm, and Würzburg. Age range was 20-80.</p> <p>3. 80 SBMA patients and 29 healthy male controls used in MRI study.</p> <p>4. Germany</p>	<p>Standardized questionnaire addressing presentation of symptoms and family history. Blood tests were performed analyzing blood glucose, lipid, and hormone levels. MRI studies were conducted to examine the adipose density of 11 SBMA patients and 29 healthy controls. Over 38 repeats was diagnostic for SBMA. Graphpad Prism 6 on Windows was used to conduct a linear regression. Statistical significance was $p < .05$</p>	<p>1. Paresis duration and CAG repeat length correlated with dehydroepiandrosterone concentration. CAG repeat and age of onset of weakness were inversely correlated ($r = -0.72$; $p < 0.0001$).</p> <p>2. Almost all patients reported muscle weakness, gynecomastia, tremor, and dysphagia.</p> <p>3. Creatine kinase did not relate to CAG repeat length or disease duration.</p> <p>4. Mean CAG repeat was 46.2 ± 3.3 (range 39.0–55.0) and mean age-at-weakness-onset was 44.4 ± 12.0 years</p>	<p>Authors mentioned limitations including recollection bias during patient interviews and absence of an age-controlled group (this could be with other muscular atrophy patients or simply healthy subjects) given that lab values are age and muscle mass dependent.</p>	<p>Controls could be used in laboratory studies so as to account for the age and muscle mass dependent effects on laboratory values. In addition, further studies could be conducted to evaluate the relationship between CAG repeat and weakness duration. For instance, Insulin-like growth factor binding protein 3 (IGF1BP3) should be evaluated with a larger cohort as only weak correlation with both CAG repeat length and weakness duration.</p>
<p>Mariotti <i>et al.</i>, (2000), Phenotypic Manifestations Associated with CAG-repeat Expansion in the Androgen Receptor Gene in Male Patients and Heterozygous</p>	<p>To report on phenotypic manifestations of SBMA in carriers and male patients.</p>	<p>1. Quantitative observational.</p> <p>2. Confirmed SBMA patients and heterozygous female carriers in Italy Male patients were between the ages 31 and 77. The pool of patients was from 30</p>	<p>DNA was extracted from peripheral blood and CAG expansion was determined by PCR. Serum levels of creatine and various hormones were measured. Relationship between CAG and age of onset was determined by linear regression and analysis (Spearman's correlation test). A protocol to indicate severity of clinical disability was used and an activity of daily living score was calculated for each symptom. Standard neurophysiological studies were performed on carrier women.</p>	<p>1. A moderate significant correlation between the number of CAG repeats and the age at onset of weakness was found ($r = -0.408$; $p < 0.02$). Muscle weakness was the most commonly reported symptom.</p> <p>2. Age at onset differed by more than 20 years in patients carrying identical CAG expansion length.</p> <p>3. Increased CAG expansion was associated with a younger age at onset. No significant correlations between CAG repeats and disability scores.</p> <p>4. Mild bulbar motor deficits (e.g. tongue fasciculations) were found in carrier women.</p> <p>5. CAG repeat range of 39-50.</p>	<p>Authors did not provide any strengths or weaknesses.</p>	<p>Authors did not provide any future considerations.</p>

s Females: A Clinical and Molecular Study of 30 Families		unrelated families. 3. 19 female carriers and 40 genetically confirmed male SBMA patients (32/70 did not have CAG expansion). 4. Italy				
Sinnreich <i>et al.</i> , (2004), Neurologic Course, Endocrine Dysfunction and Triplet Repeat Size in Spinal Bulbar Muscular Atrophy	Investigate the role of diabetes, CAG expansion length and gynecomastia as factors that modify the neurologic aspects of the expression of SBMA.	1. Quantitative longitudinal prospective. 2. Male patients with genetically confirmed SBMA (CAG repeats over 35) at the Mayo Clinic, Rochester, MN between the ages 19-75. 3. 20 male patients 4. Canada	Neurologists conducted clinical examinations. Neuropathy Impairment Score (NIS) was used to score muscle movements such as hip flexion, and score symptoms such as muscle weakness. Diabetes was determined by fasting glucose measurements of above 126 mg/dL. Gynecomastia was assessed in 17 patients via clinical examination. Bivariate correlation coefficients were used to examine disease progression, CAG repeat length etc...	1. CAG repeat size and endocrine diseases did not correlate with the rate of progression of SBMA or the neurologic involvement of the disease. 2. The number of CAG repeats and the age of onset weakness was statistically significant ($r = -0.53$, $r^2 = 29\%$, $p=0.01$). 3. CAG repeat range was from 36 to 55.	Authors did not provide any strengths or weaknesses.	Authors indicated that a larger sample size could be used such that a future study would not be underpowered and perhaps able to detect whether a relationship between CAG repeats and gynecomastia and the rate of disease progression could be due to confounding. They also indicated that more work is needed to identify specific disease modifiers.
Suzuki <i>et al.</i> , (2007), CAG Repeat Size Correlates to Electrophysiological Motor and Sensory Phenotypes in SBMA	To clarify sensory and motor nerve components of SBMA by conducting nerve conduction studies in addition to correlating CAG repeat size with electrophysiological sensory or motor dominance.	1. Quantitative observational. 2. Japanese male s with a confirmed diagnosis of SBMA patients between the ages of 31-75. 3. 106 patients with a confirmed diagnosis of SBMA and 85 normal male control subjects.	To assess the motor function of patients the following scales were used: Limb Norris score, Norris Bulbar score and ALS functional rating scale-revised (ALSFRRS-R). Median, ulnar, sural, and tibial nerves were tested in motor and sensory nerve conduction studies. Compound muscle action potentials (CMAPs), sensory conduction velocities (SCV) and sensory nerve action potentials (SNAPs) were recorded and compared to age-matched volunteer controls. Blood was extracted and CAG repeats were measured with PCR. Immunohistochemical analysis	1. CAG repeat size and age at onset are different depending on dominant phenotype: Longer CAG repeat is more closely linked with the motor phenotype, whereas a shorter CAG repeat is linked with the sensory phenotype. A greater age at onset and age at examination was seen in patients with a short CAG repeat ($p<0.0001$). 2. CMAPs, SCV, and SNAPs were decreased in SBMA patients relative to controls. 3. SNAPs are decreased in patients with a shorter CAG repeat (<47) and CMAPs were increased in patients with a longer CAG repeat (>47). 4. Mean CAG repeat size in AR gene (number) was 47.8 ± 3.1 with a range of 41-57.	Authors did not provide any strengths or weaknesses.	Authors did not provide any future recommendations.

		4.Japan	of the presence of cytoplasmic inclusions in control and SBMA primary sensory and primary motor neurons was performed. Correlations were made using SPSS software.			
Shimada <i>et al.</i> , (1995), X-linked Recessive Bulbospinal Neuropathy: Clinical Phenotypes and CAG Repeat Size in Androgen Receptor Gene	To assess clinical phenotypes and the CAG repeat size of the androgen receptor gene in 96 SBMA patients.	1.Quantitative observational. 2. Japanese male and female patients between the ages of 11 and 83 years. 3. 95 patients from 63 families. 4.Japan	Clinical symptoms (e.g. limb muscle weakness) were screened for analysis in addition to levels of creatine kinase and other substances (screened by a blood test). Onset of weakness (e.g. difficulty using stairs) was considered the onset of disease. Severity of muscle weakness was scored on deltoid, biceps brachii, iliopsoas and quadriceps femoris muscles using a grading system (0-5). Mobility of daily living was designated as the activity of daily living score (0-3). Awareness of dysphagia and gynecomastia were also reported. 75 g glucose tolerance tests were used to assess diabetes. Genomic DNA was extracted from SBMA and controls and PCR was used to identify the CAG repeats.	1. A decrease in creatine kinase concentration, muscle strength, ADL scores that was dependent on both age and duration. 2. Correlations were present between age of onset and CAG repeat size ($p<0.0001$). 3. Correlation between CAG repeat and gynecomastia ($p<0.05$). No correlation between either presence or absence of this condition and age of onset/duration. Same for diabetes mellitus. 4. If muscular weakness and ADL scores were adjusted by age they correlated with the CAG repeat length. 5. CAG repeat range, 41-52.	Authors did not provide any strengths or weaknesses.	Authors indicated that they wanted to elucidate the intergenerational transmission mechanism of biased paternal transmission of CAG repeat expansion in SBMA as the relationship in this study was not clear.
Tomik <i>et al.</i> , (2006), A Phenotypic genetic study of a Group of Polish Patients with Spinal and Bulbar Muscular Atrophy	Study phenotype-genotype correlation in a group of Polish SBMA males and heterozygous female carriers.	1.Quantitative observational. 2. Polish men with SBMA phenotypes between the ages of 20-70 and female polish carriers of the disease (aged 19-74). All participants were from the same region. 3. 11 men with SBMA and 3 female carriers were included in this study. 4.Poland	11 men with the clinical phenotype of SBMA and 3 women carriers were recruited from a cohort of 632 adult-onset motor neuron disease patients diagnosed at the Department of Neurology in Krakow. Medical documentation was reviewed for each patient and a detailed medical history was taken. Electromyography studies and nerve conduction studies were performed on eight male patients. EMG was performed at one distal muscle and one proximal muscle that was part of one lower and upper extremity at least. Reference values from literature were used. Genomic DNA was extracted and PCR was used to amplify CAG repeat segments of the AR gene. Serum levels of creatine kinase, glucose, and various	1.No correlation between CAG repeat size and either the duration of the disease or age of onset of weakness. Phenotypic expression in SBMA may not depend entirely on CAG repeats. 2. Male patients had the common signs of progressive hand tremor, slight dysphagia, nasal voice, gynecomastia, decreased potency, distal limb weakness, facial muscular weakness and orofacial fasciculations. 3. One of the carriers did present with minimal distal weakness and cramping of the legs, in addition to a history of fasciculations. 4. Mean range of CAG repeats in males was 45-52 and in females and 46-68. 5.CAG repeat range, 45-52.	Authors did not provide any weaknesses. Authors mentioned that having participants from the same region could be an advantage as they would have experienced the same genetic and environmental factors.	One patient with the clinical phenotype of SBMA (symmetrical, distal initial weakness, bulbar presentation, gynecomastia, and decreased potency) did not have an expanded CAG sequence indicating possible mosaicism. Authors recommended that he be tested again for CAG repetition size.

			hormones. Correlations between CAG repeat length and age of symptom onset (<i>i.e.</i> weakness) was determined using the Pearson product moment correlation.			
Lee <i>et al.</i> , (2005), Phenotypic variability in Kennedy's Disease: Implication of the Early Diagnostic Features	Objective was to determine the frequency of the most common clinical features of Kennedy's Disease in addition to early symptoms of SBMA.	<ol style="list-style-type: none"> 1. Quantitative observational. 2. Male Korean patients with SBMA from 17 families between the ages of 32 and 70 years. 3. 18 Male patients. 4. Korea 	<p>Patients were recruited from neuromuscular clinics in Korea. CAG repeat expansion was confirmed using PCR expansion of genomic DNA. Age at onset of each symptom was evaluated by taking a history from patients and examining their medical records. Early symptoms and signs of SBMA were recorded. Limb power was assessed by the Medical Research Council Scale. Distal muscles were also looked at to assess muscle weakness. For weakness an activity of daily living score was applied (0-3). Bulbar symptoms were also graded. Gynecomastia was identified and serum creatine kinase in addition to fasting glucose and glycohemoglobin was recorded. Nerve conduction studies were performed using standard techniques. Sensory nerve conduction studies pertained to the sural, median and ulnar nerves. Motor nerve conduction studies were conducted on peroneal, ulnar, tibial, and median. Muscle biopsies were taken from five patients and stained with hematoxylin and eosin.</p>	<ol style="list-style-type: none"> 1. Most consistent clinical findings were at evaluations perioral fasciculation with bulbar paresis, elevated CK levels, hand tremor, hyporeflexia, and limb weakness with wasting. 2. Half of all cases suffered from gynecomastia, sensory abnormalities, and had a family history of SBMA. 3. Correlation was found between CAG repeat length and the age of onset of paresis, but it was weak ($r = -0.4$). Age of onset of other symptoms and CAG repeat were not significantly correlated. 4. CAG repeat length, 45-52. 	Authors did not provide any strengths or weaknesses.	Authors recommended that future studies of a prospective nature should involve a larger number of patients in order to better characterize natural progression of disease.
Atsuta <i>et al.</i> , (2006), Natural history of spinal and bulbar muscular atrophy (SBMA): a study of 223 Japanese patients.	Investigate natural course of SBMA as assessed by 9 ADL milestones in 223 Japanese SBMA patients, and correlate this with the age of onset of specific milestones during the course of the disease with the CAG-repeat length	<ol style="list-style-type: none"> 1. Quantitative longitudinal retrospective. 2. Japanese males with an age range of 30-87. 3. 223 male patients. 4. Japan 	<p>Clinical course of SBMA was reviewed in 223 of 303 patients. PCR amplification of the CAG repeat was conducted. Patients were followed for 1 year to > 20 years by Neurologists. Initial onset and onset of nine activities of daily living (ADLs) were assessed: hand tremor, muscular weakness, requirement of a handrail, dysarthria, dysphagia, use of a cane, use of a wheelchair and development of pneumonia. Age at death and cause of death were also</p>	<ol style="list-style-type: none"> 1. Ages at onset of each ADL milestone were strongly correlated with the length of CAG repeats in the AR gene. Inverse correlation between the onset of muscle weakness and CAG repeat ($R = -0.483$, $p < 0.001$). 2. CAG-repeat length did not correlate with time intervals between each ADL milestone. 3. Levels of serum testosterone were maintained at relatively high levels even at advanced ages. 4. CAG repeat range was 40-57, with a mean of 46.6 ± 3.5. 	Authors mentioned that large sample size and the employment of marked and apparent ADL milestones that patients recognized easily was a strength. Weaknesses included: its	Authors recommended long-standing prospective studies to assess disease progression more accurately.

	in the AR gene.		investigated. Modified Rankin scale was used to assess clinical disability and serum levels of CK, AST, ALT, total cholesterol and HbA1c were measured and compared to controls.		retrospective structure, and decline curve was not successively and prospectively assessed in individual patients.	
Ni <i>et al.</i> , (2015), Genotype-phenotype correlation in Chinese patients with spinal and bulbar muscular atrophy	Elucidate the genotype-phenotype correlation among SBMA patients in the Chinese population.	<ol style="list-style-type: none"> 1. Quantitative observational. 2. Males from the Han Chinese population. 3. One hundred and fifty-five SBMA males. 4. China 	PCR amplification of CAG repeats was conducted. 86 patients had creatine kinase measurements and 32 and 44 of them further received measurements of AST and lactic dehydrogenase (LDH) respectively. 29 patients had blood total cholesterol (TC), blood low-density lipoprotein (LDL) and blood triglyceride (TG) measured. Done before a medication intervention. 86 patients underwent EMG and NCS of which compound motor action potential (CMAP) values and sensory nerve action potential (SNAP) were used. Statistical analyses were performed using SPSS, where Pearson's correlation coefficients were used to assess the relationship between CAG repeats and other factors. Analysis of covariance (ANCOVA) and Bonferroni correction were applied to neurophysiological values.	<ol style="list-style-type: none"> 1. Inverse correlation between the number of CAG repeats and the age of onset of muscle weakness $R^2 = .34$, $p < 0.0001$. 2. Average CAG repeat length was 48.6 ± 3.5. 3. Inverse correlation between CK and disease duration and age at examination ($p = 0.019$ and $p = 0.004$, respectively). In addition, all findings of nerve conduction, except the amplitudes of median nerve compound motor action potential, were positively correlated with the CAG repeat length. 4. Average length of CAG repeats of 48.6 ± 3.5 (42-61), and average age of onset of muscle weakness 44.2 ± 10.2 (24-71). 	Authors did not provide any strengths or weaknesses.	Authors recommended conducting a larger prospective study to better characterize the genotype-phenotype correlation among SBMA patients.
Song <i>et al.</i> , (2015), Clinical characteristics and genotype-phenotype correlation of Korean patients with spinal and bulbar muscular atrophy	Investigate the clinical and genetic data of Korean SBMA patients and comparing them to different ethnicities and conduct a genotype-phenotype correlation.	<ol style="list-style-type: none"> 1. Quantitative observational. 2. Korean male patients aged 20-71. 3. 40 male patients with SBMA. 4. Korea 	Nine activities of daily living were assessed which included age of onset of symptoms. Rate of disease progression was calculated. Number of CAG repeats was verified using PCR. Genotype-phenotype correlations between CAG repeat length and clinical measurements were made and analyzed using Spearman's Rank correlation tests. SPSS software was employed.	<ol style="list-style-type: none"> 1. Number of CAG repeats showed a significant inverse correlation with age of onset of symptoms, including muscle weakness ($r = -0.407$, $p = 0.009$). 2. Median ages of onset and age at diagnosis were 44.5 and 52.5 years and the median number of CAG repeats was 44 ($39.0 \square 55.0$). 3. Median interval between the median rate of disease progression and onset and diagnosis were 0.23 score/year and 5.0 years respectively. 	Authors mentioned that one weakness was that some data relied upon the patient's subjective memory. To their knowledge this was the largest cohort of SBMA patients studied in Korea and is most likely to represent Korean patients	Large-scale cohort studies with various ethnicities are needed.

						with SBMA.	
--	--	--	--	--	--	------------	--

Critical Appraisal

As all studies were quantitative in nature they were graded using the EBL Critical Appraisal Checklist (20) (see Appendix B, S1 Fig), which provides an overall score for a study based upon the validity of its population, data collection, study design, and results (see Table 4). For a study to be designated as valid, it had to have an overall validity score of 75%. As shown in Table 3, four papers failed this test (9,13,17,19) with overall scores of 67% (Doyu *et al.*, 1992), 71% (Fu *et al.*, 2013), 72% (Song *et al.*, 2015) and 62% (Tomik *et al.*, 2006), primarily due to poor population validity, but also due to poor results validity in the cases of Doyu *et al.* (1992) and Song *et al.* (2015) (9,17).

Table 4. Validity score for quantitative studies using the EBL Critical Appraisal Checklist.

Study	Population Validity %	Data collection Validity %	Study Design Validity %	Results Validity %	Overall Score %
Fu <i>et al.</i> , (2013)	56	63	80	83.3	71
Doyu <i>et al.</i> , (1992)	56	63	80	67	67
Sperfeld <i>et al.</i> , (2002)	83.3	75	80	83.3	80.4
Rosenbohm <i>et al.</i> , (2018)	78	75	100	83.3	84
Mariotti <i>et al.</i> , (2000)	83.3	75	80	83.3	80
Sinnreich <i>et al.</i> , (2004)	83.3	75	100	83.3	85.4
Suzuki <i>et al.</i> , (2007)	67	100	100	83.3	88

Shimada <i>et al.</i> , (1995)	67	63	80	100	78
Tomik <i>et al.</i> , (2006)	33	50	80	83.3	62
Lee <i>et al.</i> , (2005)	67	86	80	83.3	79.1
Atsuta <i>et al.</i> , (2006)	67	57	100	83.3	77
Ni <i>et al.</i> , (2015)	67	60	100	83.3	78
Song <i>et al.</i> , (2015)	50	86	100	50	72

Objective 1: To explore whether or not the association between CAG repeat number and age of onset of symptoms of SBMA was, or was not, significant

All thirteen eligible studies did examine the relationship between CAG repeat expansion and the age of onset of weakness in SBMA patients (5,7,9–19). These studies could be broadly divided into two groups based on how the authors assessed weakness: studies that used a scoring system to assess weakness and other signs, and studies that used informal patient interviews and/or chart reviews only. Two studies used a combination of methods from both groups (5,14). In the first group, scoring systems included the activity of daily living scores (to assess the onset and severity of weakness) (9,10,14,17), the Limb Norris score, Norris Bulbar score and ALS functional rating scale-revised to assess symptoms and signs of SBMA (12), the Neuropathy Impairment Score to assess motor function and symptoms such as weakness (18), an unspecified standard scoring system to assess symptomatology in patients (11) and a scale to grade weakness (7). The second group of studies simply used either patient interviews (7) or both chart reviews and interviews (13–15,19) or just chart reviews (16) to screen symptoms and/or signs of SBMA.

Studies can be separated into three groups regarding the relationship between CAG repeat length and the age of onset of weakness in SBMA patients (see Table 3). The first group includes articles that found a statistically insignificant inverse correlation (19) and a significant correlation (no r value was provided) (7), or no correlation (13). The second group of studies includes those that revealed either a significant moderate inverse relationship between CAG repeats and the age of onset of weakness

(5,9,10,14,16–18) or a strong inverse correlation (11,15). Note that the moderate group also contains results obtained from Lee *et al.* (2005) as, although they claimed a “weak” correlation ($r = -0.4$) (14), the correlation they identified is actually classified as moderate based on their own published r value (*e.g.*, ± 0.1 to ± 0.3 is weak, ± 0.4 to ± 0.6 is moderate, ± 0.7 to ± 0.9 is strong, and ± 1 is perfect) (21). The strength of each group of correlations is based upon accepted r value classification (21). The third group included a study that compared the number of CAG repeats with weakness onset, and related that to either motor-dominant or sensory-dominant phenotypes of weakness. Fewer CAG repeats were correlated with an older age at onset of weakness in SBMA patients and an older age at examination ($p < 0.0001$) (12).

Objective 2: To determine what minimum and maximum number of CAG repeats are associated with weakness onset in SBMA

As shown in Table 4, although all eligible studies did report the number of CAG repeats, the studies could be subdivided into three groups based on the information provided by each article as follows: 1. A group of five studies that listed the ages of participants alongside the minimum and maximum number of recorded CAG repeat number in a retrievable form (7,9,10,14,18); 2. Seven studies that listed CAG repeat number and age ranges (5,11,13,15–17,19); and, 3. One study that involved a unique experimental design, that did not fit into either of the two previous subgroups (12).

In the first group, the article by Sinnreich *et al.* (2004) reported the shortest number of CAG repeats at 36 (weakness onset at age 46) ranging up to 55 (weakness onset at

38), with the cut-off for consideration being any patient with a CAG repeat number greater than 35 (18). Mariotti *et al.* (2000) also reported a minimum CAG repeat number in the thirties, ranging from 39-50, with the patient with the fewest repeats experiencing weakness at age 50 and the two patients with the most repeats experiencing weakness at ages 35 and 31 respectively (10). This study claimed that a normal CAG repeat range was between 12 and 30, and that in SBMA it could be from 39 to 62 (10). There were three studies that reported a minimum number of CAG repeats ≥ 40 . Firstly, Doyu *et al.* (1992) who reported a range of 40-55, noting that the patient with the lowest number of repeats had an age of weakness onset of 70, compared to the patient with the most repeats who experienced weakness onset at age 25 (9). Secondly, Shimada *et al.* (1995) who identified a slightly greater minimum repeat number of 41 in a patient who experienced a later age-at-weakness-onset (age 49) than another patient who had the greatest CAG repeat number (52, with the onset of weakness at age 44) (7). Finally, Lee *et al.* (2005) reported the largest minimum CAG repeat number of 45 (age of weakness onset at 55) and a maximum repeat of 54 (onset at 39) (12).

In the second group of studies, the articles by Song *et al.* (2015) and Rosenbohm *et al.* (2018) both reported the lowest minimum CAG repeat number of the group at 39 repeats (11,17). However, their reported age ranges and average CAG repeat number differed, in that Song *et al.* (2015) reported a mean of 44 CAG repeats (range of 39 - 55) and an average age-at-onset of symptoms of SBMA was 44.5 (20.0–71.0) (17), with Rosenbohm *et al.* (2018) reporting a mean age-at-weakness-onset range of 25–75 years (44.4 \pm 12.0) and a mean length of CAG expansion of 46.2 \pm 3.3 (range 39.0–55.0) (11).

Three of the seven studies in this group reported a minimum number of CAG repeats of exactly 40. Specifically, Sperfeld *et al.* (2002) proposed that the threshold for the number of CAG repeats to be considered as normal is 38, and reported a range of 40-42 CAG repeats among their study population (15). Tomik *et al.* (2006) identified a CAG repeat number range of 45-52, claiming that the number of CAG repeats they considered to be normal was between 5 and 33, but that for SBMA it was between 40 and 62 CAG repeats (13). Atsuta *et al.* (2006) only reported a CAG repeat range of 40-57 for SBMA, with a mean of 46.6 ± 3.5 (5). Finally for this group, the two studies with the highest recorded minimum repeat number were reported in articles by Ni *et al.* (2015), who reported an average number of CAG repeats of 48.6 ± 3.5 (42-61), and an average age of weakness onset of 44.2 ± 10.2 (24-71) years (16), and Fu *et al.* (2013), who found a CAG repeat number range of between 42 and 53 (mean 47 ± 3). They proposed that a normal CAG repeat range is between 14 and 32, suggesting that anything over 40 repeats be regarded as abnormal (19).

One study, by Suzuki *et al.* (2007), did not fit into either group. This study subdivided patients with a CAG repeat size < 47 (short repeats) from those with ≥ 47 (long repeats) and then conducted electromyographic and nerve conduction studies on both groups separately (12). They reported a mean CAG repeat number of 47.8 ± 3.1 with a range of 41-57 repeats (12).

Discussion

CAG repeat number may account for approximately 60% of clinical heterogeneity in SBMA patients, with genetic, environmental and epigenetic factors also likely to play some role in influencing disease progression (1). However, the contribution of these relative unknowns aside, determining the correlation between the most commonly-mentioned SBMA symptom, weakness, and the primary clinical marker for the condition, CAG repeat number on the AR gene, might potentially uncover a strong indicator of disease onset that could be used to enable early detection, and therefore management, of SBMA. As such, this review is important and timely given that no other review to date has specifically investigated a possible connection between the age of onset of weakness in SBMA and CAG repeat length.

All of the studies investigated for this review addressed our first objective, with eleven of the thirteen indicating that a significant inverse correlation did exist between the CAG repeat number and onset of SBMA weakness (5,7,9–11,15–18) (Table 3). Although the study by Doyu *et al.* (1992) only just failed our initial screening due to poor population validity (56%), data collection validity (63%) and results validity (67%) (overall score 67%) (Table 4) we ultimately included it in this review despite the within-family comparisons which decreased its external validity (9). We felt that the use of disability scores to assess clinical severity in this paper, combined with the limited number of studies available, mitigated against its exclusion. However, notably, a single study did find that shorter CAG repeat number (<47) was associated with an *older* onset of weakness (12).

Only three out of the 13 studies included in this review failed to find a strong or even a moderate statistically significant correlation between CAG repeat number and age of onset of weakness, and these studies often had poor external validity (13,19). For example, the overall validity for the article by Tomik *et al.* (2006) was only 62%, primarily due to its poor population validity (33%; Table 4) (13). Specifically, the lack of age-matched healthy controls to compare EMG results against and the small sample size (11 SMBA patients and 3 carriers; see Table 3) significantly impacted the external validity of the study (13). However, the paper was included as it met the inclusion criteria for this review. Similarly, the study by Fu *et al.* (2013), also had a relatively low overall validity score of 71%, also mostly due to its poor external validity (50%) (Table 4). In this particular case, it was limited by the small population size and retrospective nature (indeed, the authors themselves apparently recognized this deficiency and suggested that any future characterization of the functional progression, and the clinical and electrophysiological aspects of SBMA, be conducted using larger scale prospective studies) (19). The study by Lee *et al.* (2005), which only found what the authors described as a “weak” association ($r=0.4$) between CAG repeat number and age of onset of weakness in SBMA (14), did pass screening validity with an overall validity score of 78%. However, it is notable that in this case, it too had low population validity (60%; Table 4) and a small sample size which, arguably, affect the conclusions that can be drawn from it. In this case too, the authors recommended that future prospective studies should involve a larger number of patients to better characterize the natural progression of the disease (14).

One final study, which reported only a moderate correlation between CAG repeat length and SBMA weakness (overall score 72%; Table 4), also failed screening due to its poor population and results validity (both 50%) (17). For example, this study had a poor results validity score due to its small sample size and lack of accountability for confounding factors (17). The authors recommended that a large-scale cohort study be conducted (17).

Specifically with regard to our second objective, the majority of studies examined here presented both CAG repeat number data and ages of onset of weakness such that these data could be compared across studies to determine the minimum and maximum number of repeats at age of weakness onset in SBMA (7,9,10,14,18). Rosenbohm *et al.* (2018) and Song *et al.* (2015) simply stated the CAG repeat ranges and the mean age-at-weakness-onset (11,17). Of the five studies that addressed the objective, CAG repeats ranged from the mid-thirties to the mid-fifties, which roughly coincides with the accepted marker of ≥ 38 repeats used to indicate the presence of SBMA (1), and all five studies also found that patients with larger repeat numbers had an earlier onset of weakness (7,9,10,14,18).

Future Considerations

We believe that any future SBMA studies investigating a possible connection between CAG repeat number and age of weakness onset should account for the potential effects of mosaicism as this may help to explain atypical presentations of SBMA such as one male with only 26 CAG repeats who presented with symptoms of SBMA (e.g. distal

muscle weakness) (13). Larger sample sizes would also be desirable as this would likely enable a more accurate measurement of the decline in motor function over time (Table 4). Additionally, the use of age-matched controls or at least controls suffering from other muscular atrophies should also be included in studies when conducting electromyographic and/or nerve conduction studies to provide appropriate baseline comparison data. Finally, recollection bias when reporting symptoms could be limited by combining patient interview data, chart reviews and standardized scoring systems in studies so as to minimize the likelihood of any inaccurate or misleading documentation of symptom progression.

Limitations

One limitation of this review was that it was restricted to papers written in English. This restriction meant that sixteen non-English SBMA articles did not pass the full-text screening process (Fig. 1). Another limitation was the restriction on only including articles that were available online, which meant that two potentially useful studies that could not be accessed online were excluded from our analysis (Fig. 1). Given that very little literature exists on the present topic, four articles that failed screening (9,13,17,19) were included in this review (Table 4). Studies that used only chart reviews and/or patient interviews, but not an objective scoring system to assess symptoms (7,13–16,19) are subject to recollection bias, which may have impacted the recorded age at weakness onset and the correlation of interest.

Conclusion

Weakness is the most commonly complained of symptom among SBMA patients (1).

This review of the relevant SBMA literature has shown that the majority of studies investigating this facet of SBMA pathophysiology have demonstrated an inverse correlation between the number of CAG repeats and the age of weakness onset in SBMA patients. Furthermore, most of the aforementioned studies have proposed that the minimum number of CAG repeats associated with SBMA-linked weakness falls within at least the mid-to-late thirties range or greater. By exploring and revealing the relationship between this reliable marker of SBMA and a common clinical sign of the condition as we have done here, this review not only adds to the relatively scant literature on SBMA, but also, significantly, may facilitate earlier detection of the condition and its subsequent prompt treatment.

References

1. Pradat P-F, Bernard E, Corcia P, Couratier P, Jublanc C, et al. The French national protocol for Kennedy's disease (SBMA): consensus diagnostic and management recommendations. *Orphanet J Rare Dis*. 2020 Dec;15(90):1–21.
2. Lund A, Udd B, Juvonen V, Andersen PM, Cederquist K, Davis M, et al. Multiple founder effects in spinal and bulbar muscular atrophy (SBMA, Kennedy disease) around the world. *Eur J Hum Genet*. 2001 Jun;9(6):431–6.
3. Grunseich C, Fischbeck KH. Spinal and Bulbar Muscular Atrophy. *Neurol Clin*. 2015 Nov;33(4):847–54.
4. Finsterer J, Soraru G. Onset Manifestations of Spinal and Bulbar Muscular Atrophy (Kennedy's Disease). *J Mol Neurosci*. 2016 Mar;58(3):321–9.
5. Atsuta N. Natural history of spinal and bulbar muscular atrophy (SBMA): a study of 223 Japanese patients. *Brain*. 2006 Apr 13;129(6):1446–55.
6. Spada ARL, Roling DB, Harding AE, Warner CL, Spiegel R, Hausmanowa-Petrusewicz I, et al. Meiotic stability and genotype- phenotype correlation of the binucleotide repeat in X-linked spinal and bulbar muscular atrophy. *Nature Genetics*. 1992;2:301–4.

7. Shimada N, Sobue G, Doyu M, Yamamoto K, Yasuda T, Mukai E, et al. X-Linked recessive bulbospinal neuronopathy: Clinical phenotypes and cag repeat size in androgen receptor gene. *Muscle Nerve*. 1995 Dec;18(12):1378–84.
8. Page MJ, McKenzie JE, Bossuyt PM, Boutron I, Hoffmann TC, Mulrow CD, et al. The PRISMA 2020 statement: an updated guideline for reporting systematic reviews. *BMJ* 2021;372:n71. doi: 10.1136/bmj.n71.
9. Doyu M, Sobue G, Mukai E, Kachi T, Yasuda T, Mitsuma T, et al. Severity of X-linked recessive bulbospinal neuronopathy correlates with size of the tandem cag repeat in androgen receptor gene. *Ann Neurol*. 1992 Nov;32(5):707–10.
10. Mariotti C, Castellotti B, Pareyson D, Testa D, Eoli M, Antozzi C, et al. Phenotypic manifestations associated with CAG-repeat expansion in the androgen receptor gene in male patients and heterozygous females: a clinical and molecular study of 30 families. *Neuromuscul Disord*. 2000 Aug;10(6):391–7.
11. Rosenbohm A, Hirsch S, Volk AE, Grehl T, Grosskreutz J, Hanisch F, et al. The metabolic and endocrine characteristics in spinal and bulbar muscular atrophy. *J Neurol*. 2018 May;265(5):1026–36.

12. Suzuki K, Katsuno M, Banno H, Takeuchi Y, Atsuta N, Ito M, et al. CAG repeat size correlates to electrophysiological motor and sensory phenotypes in SBMA. *Brain*. 2007 Dec 3;131(1):229–39.

13. Tomik B, Partyka D, Sułek A, Kurek-Gryz EA, Banach M, Ostrowska M, et al. A phenotypic-genetic study of a group of Polish patients with spinal and bulbar muscular atrophy. *Amyotroph Lateral Scler*. 2006 Jan;7(2):72–9.

14. Lee JH, Shin JH, Park KP, Kim IJ, Kim CM, Lim JG, et al. Phenotypic variability in Kennedy's disease: implication of the early diagnostic features. *Acta Neurol Scand*. 2005 Jul;112(1):57–63.

15. Sperfeld AD, Karitzky J, Brummer D, Schreiber H, Häussler J, Ludolph AC, et al. X-linked Bulbospinal Neuronopathy: Kennedy Disease. *Arch Neurol*. 2002 Dec 1;59(12):1921.

16. Ni W, Chen S, Qiao K, Wang N, Wu ZY. Genotype-Phenotype Correlation in Chinese Patients with Spinal and Bulbar Muscular Atrophy. Borchelt DR, editor. *PLOS ONE*. 2015 Mar 26;10(3):1–9.

17. Song JS, Kim KA, Min JH, Ki CS, Kim JW, Sung DH, et al. Clinical Characteristics and Genotype-Phenotype Correlation of Korean Patients with Spinal and Bulbar Muscular Atrophy. *Yonsei Med J*. 2015;56(4):993–97.

18. Sinnreich M, Sorenson EJ, Klein CJ. Neurologic Course, Endocrine Dysfunction and Triplet Repeat Size in Spinal Bulbar Muscular Atrophy. *Can J Neurol Sci.* 2004 Aug;31(3):378–82.
19. Fu SC, Kuo HC, Chu CC, Wu YR, Ro LS, Liu CS, et al. Long-term follow-up of spinal and bulbar muscular atrophy in Taiwan. *J Formos Med Assoc.* 2013 Jun;112(6):326–31.
20. Glynn L. EBLIP Critical Appraisal Checklist. Memorial University of Newfoundland. <http://ebltoolkit.pbworks.com/f/EBLCriticalAppraisalChecklist.pdf> [accessed 2021 November 14].
21. Akoglu H. User's guide to correlation coefficients. *Turk J Emerg Med.* 2018 Sep;18(3):91–3.

Supporting Information

S1 File. Appendix A search terms.

S1 Fig. Appendix B EBL data.

